Alumis filed Friday for an initial public offering to raise money for Phase III trials of a potential rival to Bristol Myers ...

Skye Bioscience announced Monday it is stopping all work on an eye disease candidate, SBI-100 Ophthalmic Emulsion, and its ...

Moderna on Monday unveiled Phase III data for its investigational combination vaccine mRNA-1083, which demonstrated a ...

The FDA on Friday approved a label expansion for GSK’s respiratory syncytial virus vaccine Arexvy, allowing its use in adults ...

Eli Lilly on Saturday released detailed data from the Phase II SYNERGY-NASH study, demonstrating the potential of its ...

Pfizer’s oral antiviral Paxlovid (nirmatrelvir/ritonavir) does not appear to significantly ease symptoms in patients with ...

Tempting as it may be to turn to full automation to meet burdensome requirements, the potential for hallucination and other ...

LSD, ketamine, ibogaine and related treatments are moving forward in clinical trials for substance use disorders, including ...

With 164 clinical trials assessing 127 drugs in the pipeline, momentum in the Alzheimer’s space is on an upward swing—and ...

GLP-1 receptor agonists are very effective at helping obese and overweight patients lose weight, but reductions in muscle ...

Biomea Fusion’s early-stage investigational diabetes treatment BMF-291 has been slapped with a full FDA clinical hold on its ...

After rejecting a previous takeover offer from Future Pak, Vanda Pharmaceuticals is now fielding another acquisition proposal ...